Invitae Corporation Stock Price, News & Analysis

Invitae Corporation (NYSE: NVTA) announces it will report Q3 2021 financial results on November 8, 2021. The company will host a conference call at 4:30 p.m. Eastern to discuss the results and highlights. Participants can register to access the call through a provided link. A live webcast will also be available, including a slide deck, and a replay will be accessible post-call. Invitae aims to improve healthcare through comprehensive genetic information and is focused on making genetic testing more accessible and affordable.

Invitae (NYSE: NVTA), UCL, and the Francis Crick Institute presented new findings from the TRACERx lung cancer study, emphasizing the efficacy of liquid biopsies in detecting minimal residual disease (MRD) earlier than traditional imaging methods. The ECLIPSE tool, used alongside Invitae's Personalized Cancer Monitoring (PCM) liquid biopsy assay, showed enhanced detection of NSCLC relapse in 75 patients. These advances may revolutionize personalized cancer treatment and improve patient outcomes by enabling earlier intervention and more effective therapy monitoring.

Outcomes4Me Inc. has partnered with Invitae Corporation (NYSE: NVTA) to enhance education and access to genetic testing for breast cancer patients. This collaboration integrates Invitae's clinical-grade genetic testing with Outcomes4Me's innovative mobile app, revolutionizing patient support and treatment options. Nearly 46% of patients eligible for testing were unaware of their options. The app facilitates genetic counseling and testing integration, empowering patients to make informed decisions. This partnership aims to enhance personalized care and improve health outcomes by providing accessible resources to cancer patients.

Invitae (NYSE: NVTA) presented research at the National Society of Genetic Counselors conference, emphasizing the role of genetic testing in improving clinical management for epilepsy patients. The study revealed that nearly half of the patients experienced changes in management after genetic testing, leading to positive outcomes in 75% of cases, including seizure reduction and behavioral improvements. These findings support the importance of genetic testing in enhancing healthcare efficiency and outcomes, particularly for the approximately 50 million people affected by epilepsy worldwide.

Invitae (NYSE: NVTA) announced its agreement to acquire Ciitizen for approximately $325 million. This acquisition aims to enhance Invitae's platform by integrating Ciitizen's consumer health tech solutions, allowing patients to manage their genomic and clinical data more effectively. The deal includes $125 million in cash and about 7 million shares of Invitae's common stock. The integration is expected to empower Invitae's patient-centric data ecosystem, driving better healthcare outcomes and supporting research efforts. The transaction is set to close this month.

Invitae Corporation (NYSE: NVTA) will participate in a virtual fireside chat during the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 12:30 PM Eastern Time. The event will feature members of Invitae's management team discussing key topics related to the company.

A live webcast of the chat can be accessed through the investors section of Invitae's website, with a replay available shortly thereafter.

Invitae's mission focuses on integrating genetic information into mainstream medicine, aiming to enhance healthcare for billions globally.

Invitae Corporation (NYSE: NVTA) announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021. The management team will engage in a fireside chat at 11:00 a.m. PT, while CEO Sean George will join the NGS Technologies panel at 1:00 p.m. PT. Interested investors can access live webcasts through the company’s investor relations site, with replays available shortly after the events. Invitae aims to integrate comprehensive genetic information into healthcare, enhancing test quality and accessibility.

Invitae Corporation (NYSE: NVTA) reported strong preliminary financial results for Q2 2021, achieving a revenue of $116.3 million, up 152% from $46.2 million in Q2 2020. Billable volume also rose 154% to 287,000 tests. The company increased its 2021 revenue guidance to between $475-$500 million. Despite a net loss of $129 million, down from $166.4 million year-over-year, cash reserves improved significantly to $1.54 billion. Invitae continues to expand partnerships, including with Medneon and Children's National Hospital, to enhance genetic testing and research capabilities.

Volpara Health has partnered with Invitae Corporation to integrate Invitae's genetic testing services into Volpara's breast care platform for U.S. customers. This collaboration aims to enhance access to personalized breast cancer screening and risk assessment. By combining Volpara's risk assessment software with Invitae's genetic testing, patients can make informed decisions regarding supplemental imaging and genetic testing. The integration is designed to streamline the ordering process and improve patient outcomes in cancer care.